Home > AZD0364

molecules of the month

AZD0364

oral reversible ERK1/2 kinase inhibitor

combo eff. w/ MEKi in mKRAS model; in Ph. I

from historical kinase sel. data, SBDD + opt.

Mol. Cancer Ther. Dec. 3, 2020

AstraZeneca, Cambridge, UK

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.